Technical Analysis for ZBIO - Zenas BioPharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
20 DMA Resistance | Bearish | -1.78% | |
NR7 | Range Contraction | -1.78% | |
Narrow Range Bar | Range Contraction | -1.78% | |
Wide Bands | Range Expansion | -1.78% | |
20 DMA Resistance | Bearish | -2.65% | |
Outside Day | Range Expansion | -2.65% | |
Wide Bands | Range Expansion | -2.65% | |
NR7 | Range Contraction | 0.65% | |
Inside Day | Range Contraction | 0.65% |
Alert | Time |
---|---|
10 DMA Support | 2 days ago |
Down 5% | 2 days ago |
60 Minute Opening Range Breakdown | 2 days ago |
Up 1% | 2 days ago |
Down 3% | 2 days ago |
Get this analysis on your stocks daily!
- Earnings date: Unknown
Zenas BioPharma, Inc. Description
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Immunology Immune System Antibodies Monoclonal Antibody Multiple Sclerosis Glycoproteins Systemic Lupus Erythematosus Immunoglobulin E Warm Autoimmune Hemolytic Anemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 26.2508 |
52 Week Low | 5.83 |
Average Volume | 292,505 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 9.06 |
20-Day Moving Average | 7.77 |
10-Day Moving Average | 7.46 |
Average True Range | 0.81 |
RSI (14) | 43.82 |
ADX | 26.36 |
+DI | 18.56 |
-DI | 26.39 |
Chandelier Exit (Long, 3 ATRs) | 8.18 |
Chandelier Exit (Short, 3 ATRs) | 8.25 |
Upper Bollinger Bands | 8.77 |
Lower Bollinger Band | 6.78 |
Percent B (%b) | 0.47 |
BandWidth | 25.56 |
MACD Line | -0.54 |
MACD Signal Line | -0.71 |
MACD Histogram | 0.1641 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 8.39 | ||||
Resistance 3 (R3) | 8.37 | 8.13 | 8.28 | ||
Resistance 2 (R2) | 8.13 | 7.96 | 8.14 | 8.24 | |
Resistance 1 (R1) | 7.92 | 7.85 | 7.80 | 7.94 | 8.20 |
Pivot Point | 7.68 | 7.68 | 7.62 | 7.69 | 7.68 |
Support 1 (S1) | 7.47 | 7.51 | 7.35 | 7.48 | 7.22 |
Support 2 (S2) | 7.23 | 7.40 | 7.23 | 7.18 | |
Support 3 (S3) | 7.01 | 7.23 | 7.14 | ||
Support 4 (S4) | 7.03 |